Editorial: New lights Through Old Windows: Metformin and Derivatives as Anti-Cancer Treatments
Abstract
The current theme issue is intended to focus on the advances and the development of drug repurposing and strategies for cancer treatment. The issue contains the contributions from researchers studying various aspects of drug repurposing and screening for anticancermanagement with a particular interest in metformin (dimethylbiguanide) as well as other small marketed drugs. Metformin is the recommended first line of treatment of type 2 Diabetes Mellitus. Recently, metformin is gaining international interest for its potential use to treat/prevent different types of cancer, cardiovascular disease, ageing, and neurological disorders. Several studies reported the potential anticancer activity of metformin that promoted the initiation of tens of clinical trials that aimed to investigate its potential against endometrial, prostate, pancreas, lung and breast cancer. Nonetheless, uncertainties still exist with respect to understanding the cellular mode of action of metformin, its antiproliferative ability as well as the effective antiproliferative concentration. In their article “Metformin Adjunct With Antineoplastic Agents for the Treatment of Lung Cancer: A Meta-Analysis of Randomized Controlled Trials and Observational Cohort Studies” (Luo et al.) that evaluated the scientific literature on the efficacy of the combinational use of metformin and anticancer agents on lung cancer survival in both diabetic and non-diabetic patients. Briefly, the study is a comprehensive meta-analyses…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.